JAZZ241115P100000
- 1.20
- +0.38+46.34%
Jazz Pharmaceuticals Newsroom
Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024
Jazz Pharmaceuticals Is Maintained at Outperform by RBC Capital
Jazz Pharmaceuticals Analyst Ratings
RBC Capital Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $179
Express News | Jazz Pharmaceuticals PLC : RBC Raises Target Price to $179 From $175
Jazz Pharmaceuticals Relocates Operations to New Premises
Express News | Jazz Pharmaceuticals : Existing Lease to Terminate Effective June 30, 2025
Express News | Jazz Pharmaceuticals : Unit Terminates Lease Agreement With the Board of Trustees of the Leland Stanford Junior University
Is Jazz Pharmaceuticals Plc (JAZZ) the Most Promising Biotech Stock According to Hedge Funds?
JAZZ Stock Soars After Combo Therapy Meets Goal in Lung Cancer Study
Truist Financial Initiates Jazz Pharmaceuticals(JAZZ.US) With Buy Rating
BofA Securities Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $172
Barclays Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $200
Barclays Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Positive Phase 3 Results and Market Expansion Drive Buy Rating for Jazz Pharmaceuticals
Jazz Pharmaceuticals Reports Positive Preliminary Results in Clinical Trial of Potential Lung Cancer Treatment
Express News | Pharma Mar - Jazz Plans to Submit Supplemental New Drug Application to U.S. FDA and Pharmamar Will Submit Marketing Authorisation Application to EMA in First Half of 2025
Express News | Pharma Mar - Combination of Lurbinectedin and Atezolizumab Demonstrated a Statistically Significant Improvement in Primary Endpoints of Overall Survival and Progression-Free Survival
Express News | Jazz Pharmaceuticals PLC - Combination Well-Tolerated With No New Safety Signals
Express News | Jazz Pharmaceuticals PLC - Plans to Submit Snda for Combination Therapy in H1 2025